1 1.

Slides:



Advertisements
Similar presentations
Is Radical Prostatectomy Adequate For High Risk Prostate Cancer?
Advertisements

NPCA data collection on men undergoing radical surgery for prostate cancer Paul Cathcart, NPCA Urology Project Coordinator.
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Prostate Cancer Radical Prostatectomy
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
PROSTATE CANCER EXPECTED MANAGEMENT & CURATIVE TREATMENT Dr. Abdullah A. Ghazi (R5) KSMC.
Steven Joniau Filip Ameye
PROSTATE CANCER LETS DEBATE !!!! Dr Fred C Tyler MBChB FRCS FCS UROL.
M. Wirth Department of Urology, Technical University of Dresden Adjuvant or Salvage Radiotherapy after Radical Prostatectomy.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
© Cancer Research UK 2008 Registered charity number Prostate cancer – UK December 2009.
Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma
Howard M. Sandler, MD University of Michigan Medical School
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
Active Surveillance or Watchful Waiting – How do They Apply to Your Patients? 蒲永孝 臺大醫院泌尿部主任 臺大醫學院泌尿科教授 臺灣楓城泌尿學會理事長 台灣泌尿科醫學會常務理事 臺大醫學院臨床醫學研究所博士.
Updated 5-year Biochemical Relapse-Free Survival after Prostate Brachytherapy Jenny P. Nobes St. Luke’s Cancer Centre, The Royal Surrey County Hospital,
Laparoscopic Radical Prostatectomy: Oncological and Functional Outcomes Following Fellowship Training. Introduction Radical Prostatectomy (RP) is a technically.
Robert Dreicer, M.D., M.S., FACP Chair Dept of Solid Tumor Oncology
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
What’s new in PCA... Steven Joniau University Hospitals Leuven, Belgium EAU Guidelines 2010 update.
MpMRI in Prostate cancer A Urologist’s Perspective Diagnosis Treatment Choice Surgical Planning Dr. Peter Heathcote, Adjunct Professor APCRC-Q QUT, Senior.
Active surveillance in prostate cancer Dr John Yaxley Urological & robotic surgeon.
Hormone treatment combined with radiotherapy
Oncology 12 Locally Advanced Prostate Cancer
Combined Modality Treatment of Locally Advanced Prostate Cancer: Radiation Therapy (RT) with Concurrent Androgen Deprivation Therapy (ADT) Howard Sandler.
South West Public Health Observatory South West Regional Public Health Group Prostate cancer in England and the South West Sean McPhail 1, Paul Eves 1,
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
LOCAL TREATMENT OF OLIGOMETASTATIC DISEASE IN PROSTATE CANCER: LYMPHADENECTOMY Alberto Briganti, MD, fEBU Department of Urology Chair, Prostate Cancer.
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Updates in the Management of Localized Prostate Cancer
Per-Anders Abrahamsson Department of Urology Malmö University Hospital
Conseguenze cliniche della sorveglianza attiva Aldo Massimo Bocciardi
Surgical Treatment in Locally Advanced Prostate Cancer
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital
Bladder Cancer and Prostatic Cancer
Radical Prostatectomy in pN+ Prostate Cancer
Nat. Rev. Urol. doi: /nrurol
Decipher Prostate, Decipher Bladder and Decipher GRID
The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis Urol Int 2017;99:
RELAZIONE TRA “STAGE MIGRATION” E
Prostate cancer mortality as a factor of Gleason score and age at diagnosis in men managed conservatively. (Adapted, with permission, from Albertsen PC.
Current role of androgen deprivation after surgery or radiotherapy of high-risk PCa Morgan Roupret, MD, PhD Pitié Salpétrière Hospital University Paris.
MANAGEMENT OF SMALL RENAL TUMORS: Current Evidence
2017 USPSTF Draft Recommendations for Prostate Cancer Screening
N.N. Alexandrov National Cancer Centre
Dr Tak-Hing Bill WONG Consultant Urologist & Head
Prostate Cancer: Highlights from 2006
Apollo Gleneagles Hospitals,
Figure 3 Semantic model of the active surveillance (AS) timeline
Hormone Therapy for Prostate Cancer: Exploring Current Controversies
SORVEGLIANZA ATTIVA DELLE PICCOLE MASSE RENALI
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Volume 73, Issue 4, Pages (April 2018)
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Volume 58, Issue 1, Pages 1-7 (July 2010)
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Active Surveillance for Low Risk Prostate Cancer
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
1 1.
Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database 
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Role of Radical Prostatectomy in metastatic Prostate Cancer
Long-Term Hormonal Therapy: Who Would Benefit?
Prostate Cancer Update
Management of Prostate Cancer: Global Strategies
Fig. 4 High P-eIF2α expression in human prostate tumors with loss of PTEN function is associated with increased risk of metastasis or death after surgery.
Surgery for high-risk prostate cancer: The results of first 80 cases
Prostate cancer screening beyond PSA – STHLM3 and/or MRI
Presentation transcript:

1 1

punto di vista dell’urologo Ospedale “San Giovanni Bosco” Categorie di rischio: punto di vista dell’urologo Alessandro Giacobbe Ospedale “San Giovanni Bosco” S.C. Urologia Torino 2 2

“Advanced” PCa

Treatment Options Surgery RT Cryo/Other Multimodal Approach

Treatment Options Surgery RT Cryo/Other Multimodal Approach

Non tutti i t3 c sono alto rischio

10-yr PCSM >80% Non tutti gli alti rischi sono uguali…..

15-yr Radical Prostatectomy Cancer Specific Mortality Gleason score≤6 15-yr Cancer specific Survival ≥99% Gleason score 7(3+4) 15-yr Cancer specific Survival 98% Gleason score 7(4+3) 15-yr Cancer specific Survival 94% Gleason score 8-10 15-yr Cancer specific Survival 65%

15-yr Radical Prostatectomy Cancer Specific Mortality Gleason score≤6 15-yr Cancer specific Survival ≥99% Gleason score 7(3+4) 15-yr Cancer specific Survival 98% Gleason score 7(4+3) 15-yr Cancer specific Survival 94% K prostata hann molto bassa mortatlita mentre questo e un tumore vero attenione duvers Gleason score 8-10 15-yr Cancer specific Survival 65%

Locally Advanced CaP 5 Yr 10 Yr 15 Yr BPFS 45-62% 43-51% 38-49% CSS 90-99% 85-92% 62-84% OS 90-96% 76-77% Gerber, G.S., et al.. Eur Urol, 1997. 32: 385 Hsu, C.Y., et al. Eur Urol, 2007. 51: 121 Joniau, S., et al. Eur Urol, 2015. 67: 319 Xylinas, E., et al. BJU Int, 2009. 103: 1173

Locally Advanced CaP 5 Yr 10 Yr 15 Yr BPFS 45-62% 43-51% 38-49% CSS 90-99% 85-92% 62-84% OS 90-96% 76-77% Gerber, G.S., et al.. Eur Urol, 1997. 32: 385 Hsu, C.Y., et al. Eur Urol, 2007. 51: 121 Joniau, S., et al. Eur Urol, 2015. 67: 319 Xylinas, E., et al. BJU Int, 2009. 103: 1173

Locally Advanced CaP 5 Yr 10 Yr 15 Yr BPFS 45-62% 43-51% 38-49% CSS 90-99% 85-92% 62-84% OS 90-96% 76-77% Gerber, G.S., et al.. Eur Urol, 1997. 32: 385 Hsu, C.Y., et al. Eur Urol, 2007. 51: 121 Joniau, S., et al. Eur Urol, 2015. 67: 319 Xylinas, E., et al. BJU Int, 2009. 103: 1173

Treatment Options Surgery RT Cryo/Other Multimodal Approach

2.5 fold increased risk of metastasis

Treatment Options Surgery RT Cryo/Other Multimodal Approach

Treatment Options Surgery RT Cryo/Other Multimodal Approach

Adjuvant RT recommended for pT3 pts

Our Clinical Practice Age <70, Gleason ≤ 6, PSA < 10 Nerve sparing prostatectomy Active Surveillance (1-2 pos core/12 or more) Gleason score 7 or PSA >10 Age <70 Rad Prostatectomy and PLND Age >70 Radiotherapy Gleason score ≥8 Surgery + Radiotherapy + ADT (intermittent)